Storm Therapeutics Limited

Padlock Therapeutics, Inc.

Max-planck-gesellschaft Zur Forderung Der Wissenschaften E.v.

Mark Peter Ridgill

Frederick Arthur Brookfield

Heather Tye

Jon Shepherd

Mirco Meniconi

David James Hardick

Elizabeth Jane Thomas

Wesley Peter Blackaby

Christian Bubert

Gnanasambandam Kumaravel

Rajesh Devraj

Pui Leng Loke

Cristina Lecci

Carl Leslie North

Adrian Kotey

John Michael McCall

Eddine Saiah

Michael Frederick Parker

Hairuo Peng

Kai Peter Johnsson

Mark Joseph Tebbe

Laura Gleave

Holly Atton

Elise Gadouleau

Shelley Anne Parrott

Jordan Palfrey

Philip Stephen Kerry

Edward Beaumont

Mark Anthony Kerry

Nat Monck

Thomas Krulle

Craig Avery

Steven Mark Bromidge

Nathaniel J Monck

Katarzyna Irena Gorska

Sophie Cooper

Steve Bromidge

Lee Bowles

Nathaniel Julius Thomas Monck

Steve Brombridge

Pui Loke

Mark Kerry

Adrian Kotei Kotey

The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity: X—Y—Z5 (I) wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity 10 is implicated.

METTL3 inhibitory compounds

The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity:X—Y—Z   (I)wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.

Polyheterocyclic compounds as METTL3 inhibitors

The present invention relates to compounds of formula (I) that function as inhibitors of METTL3 (N6-adenosine-methyltransferase 70 kDa subunit) enzyme activity:X&#x2014;Y&#x2014;Z&#x2003;&#x2003;(I)wherein X, Y and Z are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, and autoimmune diseases, as well as other diseases or conditions in which METTL3 activity is implicated.

The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

Heteroaryl inhibitors of PAD4

Bicyclic inhibitors of PAD4

Inhibitors of sepiapterin reductase and uses of sepiapterin reductase inhibitors in analgesia, treatment of acute and chronic pain, anti-inflammation, and immune cell regulation are disclosed.

Sepiapterin reductase inhibitors

Growing community of inventors

Abingdon, United Kingdom

Mark Peter Ridgill